3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hormone Receptor Positive Breast Cancer
1
Hemangioma
1
Hemangioendothelioma
1
Interventions
Magnetic Resonance Spectroscopy
8
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
lutetium Lu 177 dotatate
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
pembrolizumab
1
neratinib
1
cemiplimab
1
brigatinib
1
Watchful Waiting
1
Vincristine
1
Vemurafenib
1
Temozolomide
1
Radiotherapy, Conformal
1
Radiotherapy
1
Radiation
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ependymoma
×
Everolimus
×
90 days
×
Clear all
No trials found.